BioCardia, Inc.
Moat Score — BioCardia, Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Holds 70+ issued/pending patents, exclusive licenses from Biomet Biologics and CART-TECH, and FDA Breakthrough Device Designation for CardiAMP, but no approved product yet exists to monetize this IP. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Pre-revenue clinical-stage company with no manufacturing scale or cost structure advantage; relies on a third party (Biomet Biologics) for autologous cell processing. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | No commercial product on the market, so there is no pricing power to speak of; near-term cash comes from CMS trial reimbursement caps, not market-set pricing. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A cell-therapy and delivery-device business with no user, data, or platform network effects. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | If Helix or CardiAMP is eventually adopted by physicians and health systems, procedural training and CMS coverage pathways could create modest switching friction, but this is entirely speculative pre-approval. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | A single small clinical-stage company running trials at a handful of sites; no evidence of a market too small to attract competition, and it in fact faces several well-funded cell-therapy rivals. |